English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 0/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ❌ Growth failed
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 19.29%
Price change 2019 → 2020: 164.49%
Price change 2020 → 2021: -16.78%
Price change 2021 → 2022: -89.15%
Price change 2022 → 2023: 188.54%
Price change 2023 → 2024: -72.91%
Price change 2024 → 2025: -70.22%
Price change 2025 → 2026: 176.13%
Price change 2026 (year to date): 174.29%
Financial growth
Revenue CAGR (8 years): -1.01%
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.71
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -6.68
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 0.00% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="DOCM.SW" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| DocMorris AG | – | 0.71 | +5.7 % | 🔒 |
| Clariane SE | 574.8 | 2.16 | +12.4 % | – |
| Lumibird S.A. | 38.8 | 0.71 | +9.8 % | – |
| Valneva SE | – | 1.95 | +22.4 % | – |
| Emeis | – | 6.11 | +11.4 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by DocMorris AG over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 1.8 bn | -165 m | -9.2 % | n/a |
| 2021 | 2.1 bn | -274 m | -13.1 % | +16.9 % |
| 2022 | 1.1 bn | -208 m | -18.4 % | -46.1 % |
| 2023 | 1.2 bn | 99.8 m | 8.5 % | +4.1 % |
| 2024 | 1.2 bn | -118 m | -9.6 % | +4.9 % |
| 2025 | 1.4 bn | -163 m | -11.9 % | +10.6 % |
Amounts converted to USD. Source: published annual accounts, collected on 30/10/2026.
Accounts and financial health
Balance sheet and cash flow published by DocMorris AG over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 278 m | 156 m | 104 m | 95.4 m | 150 m |
| Total Debt | 525 m | 529 m | 331 m | 312 m | 289 m |
| Net Debt | 247 m | 403 m | 277 m | 217 m | 169 m |
| Equity | 485 m | 351 m | 431 m | 340 m | 409 m |
| Total assets | 1.3 bn | 1.1 bn | 866 m | 778 m | 825 m |
| Operating cash flow | -131 m | -97.3 m | -87.4 m | -26.6 m | -88.3 m |
| Investments (capex) | 63.5 m | 59.3 m | 5.0 m | 1.4 m | 27.3 m |
| Free cash-flow | -194 m | -157 m | -115 m | -55.2 m | -90.0 m |
| Share buybacks | 4,000 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in CHF, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 02/11/2026.
Valuation and competitors
DocMorris AG compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| DocMorris AG | 939 m | n/a | -11.9 % |
| IVF Hartmann Holding AG VBSN.SW | 361 m | 14.3 | 11.3 % |
| COLTENE Holding AG CLTN.SW | 357 m | 19.7 | 6.2 % |
| Santhera Pharmaceuticals Holding AG SANN.SW | 284 m | n/a | -63.8 % |
| Molecular Partners AG MOLN.SW | 134 m | n/a | 0.0 % |
| Ascom Holding AG ASCN.SW | 229 m | 11.0 | 5.2 % |
| SHL Telemedicine Ltd. SHLTN.SW | 45.9 m | n/a | -26.2 % |
| Addex Therapeutics Ltd ADXN.SW | 3.5 m | n/a | -3,889.6 % |
| EvoNext Holdings S.A. EVE.SW | 19.9 m | n/a | 0.0 % |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 30/10/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
DocMorris AG: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 19/08/2026 | -1.10 | -3.71 | n/a |
| 08/05/2025 | -2.47 | -2.27 | n/a |
| 13/03/2025 | -1.59 | -2.55 | n/a |
| 20/08/2024 | -1.59 | -2.55 | n/a |
Stock splits
| Date | Operation |
|---|---|
| 22/11/2018 | split: 132 shares for 125 |
Factual data: ex-dividend history and earnings calendar, as of 03/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in DocMorris AG.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 01/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about DocMorris AG
What is the DocMorris AG share price?
Latest recorded price: 15.32 CHF on 30/10/2026, for a market cap of 939 m USD.
What is the revenue of DocMorris AG?
1.4 bn USD for fiscal year 2025, with net income of -163 m USD (net margin -11.9 %).
Is DocMorris AG stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN CH0042615283).
How many employees does DocMorris AG have?
1,454 full-time employees according to the latest published profile.
Who runs DocMorris AG?
Walter Hess is the company's chief executive.